BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1377 related articles for article (PubMed ID: 28355305)

  • 1. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
    Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
    Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
    Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
    J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.
    Fan W; Zhang Y; Wang Y; Yao X; Yang J; Li J
    PLoS One; 2015; 10(3):e0119312. PubMed ID: 25742141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI).
    Ji F; Liang Y; Fu SJ; Guo ZY; Shu M; Shen SL; Li SQ; Peng BG; Liang LJ; Hua YP
    BMC Cancer; 2016 Feb; 16():137. PubMed ID: 26907597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis.
    He C; Zhang Y; Lin X
    J Gastrointest Surg; 2018 Jun; 22(6):989-997. PubMed ID: 29435900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
    Pinato DJ; Sharma R
    Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).
    Lin XJ; Li QJ; Lao XM; Yang H; Li SP
    BMC Cancer; 2015 Oct; 15():707. PubMed ID: 26470869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization.
    Liu C; Li L; Lu WS; Du H; Yan LN; Yang JY; Wen TF; Zeng GJ; Jiang L; Yang J
    Sci Rep; 2017 Oct; 7(1):13873. PubMed ID: 29066730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma.
    Xu Y; Yuan X; Zhang X; Hu W; Wang Z; Yao L; Zong L
    Medicine (Baltimore); 2021 Jun; 100(25):e26506. PubMed ID: 34160470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    Liu C; Li L; Lu WS; Du H; Yan LN; Wen TF; Wei WR; Jiang L; Xu MQ
    BMC Cancer; 2018 Feb; 18(1):216. PubMed ID: 29466970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.
    Pang Q; Zhou L; Qu K; Cui RX; Jin H; Liu HC
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):60-70. PubMed ID: 29189392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
    Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
    Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L; Gou CY; Li JY; Achakzai R; Li XH
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation.
    Yang XG; Huang YC; Wang CH; Sun YY; Huang Z; Xu GH
    Cancer Invest; 2022 Jul; 40(6):494-504. PubMed ID: 35404178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.
    Chu MO; Shen CH; Chang TS; Xu HW; Yen CW; Lu SN; Hung CH
    Sci Rep; 2018 Nov; 8(1):16611. PubMed ID: 30413724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.